Orchid Chemicals & Pharmaceuticals Ltd. (524372.BY) said Thursday it has settled a patent litigation over its generic version of Forest Laboratories Inc.'s (FRX) Namenda tablets used in the treatment of Alzheimer's disease.

Orchid will be able to start selling memantine tablets--the generic form of Namenda--in January 2015, or earlier in certain circumstances, the Indian generic drug maker said in a statement.

The company said additional terms of the settlement are confidential.

Namenda had sales of about $950 million in 2009 in the U.S., it added.

-By Rumman Ahmed, Dow Jones Newswires; 91-9845104173; rumman.ahmed@dowjones.com
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From May 2024 to Jun 2024 Click Here for more Forest Road Acquisition Charts.
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Jun 2023 to Jun 2024 Click Here for more Forest Road Acquisition Charts.